Carla M. Canuso

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Journal: Focus (American Psychiatric Publishing)

Published: August 01, 2026

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Journal: The American journal of psychiatry

Published: October 01, 2025

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

Journal: JAMA psychiatry

Published: July 02, 2025

Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study.

Journal: Journal of affective disorders

Published: May 19, 2025

Making Progress in Clinical Trials for Suicide Prevention: A Review.

Journal: JAMA psychiatry

Published: February 12, 2025

Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: June 03, 2024

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Journal: Journal of the American Academy of Child and Adolescent Psychiatry

Published: May 30, 2024

Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: December 31, 2023

Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc.

Journal: Psychological medicine

Published: August 23, 2023

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: May 24, 2023

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics.

Journal: Neuropsychiatric disease and treatment

Published: April 13, 2023

Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone.

Journal: Brain and behavior

Published: November 23, 2022

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study.

Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study.

Making Progress in Clinical Trials for Suicide Prevention: A Review.

Making Progress in Clinical Trials for Suicide Prevention: A Review.

Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study.

Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study.

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.

Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.

Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc.

Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc.

Effects ﻿of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Effects ﻿of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics.

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics.

Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone.

Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone.

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).